 The company is expanding that portfolio by using its proprietary Retrocyte Display® discovery system to generate fully human therapeutic antibody drug candidates.The platform is a high-throughput approach incorporating IgG format human antibody libraries expressed in mammalian B-lineage cells.The Prophage Series of patient-specific cancer vaccine candidates can also enhance the immune system's response to tumors.